$JBTM

JBT Marel (JBTM) reported Q2 2026 revenue of $981 million, up 5% YoY, with Protein Solutions at $467 million (+11%) and Prepared Food and Beverage Solutions at $514 million (flat). Adjusted EBITDA was $168 million (17.1% margin) and adjusted diluted EPS was $1.95. Inbound orders were $1.03 billion and backlog $1.54 billion. Full-year revenue guidance is $3.99B to $4.065B.

JBT Marel reported a Q2 2026 earnings call with third straight quarter of orders above $1B, driven by double-digit Prepared Food and Beverage growth and poultry investment. Prepared Food revenue was flat due to logistics and production inefficiencies from a ~15% global footprint reduction. Full-year 2026 guidance was maintained; 2028 targets include $25M-$30M cost synergies and 20% adjusted EBITDA margin. A $200M buyback was authorized.

JBT Marel (JBTM) shares fell about 7.1% after Q2 adjusted EPS of $1.95 missed the $2.02 consensus. The company also cut full-year adjusted EPS guidance to $8.10 at the midpoint, down 1.8% from prior outlook. The article notes JBTM is volatile and highlights broader industrial and oil-rate sensitivity.

JBT MAREL Corp (JBTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release JBT Marel Corporation 333 West Wacker Drive Suite 3400 Chicago, IL 60606 JBT Marel Corporation Reports Second Quarter 2026 Results Second Quarter 2026 Highlights: ◦ Continued strong demand with orders exceeding $1 billion; revenue was $981 million, resul

JBT Marel (NYSE: JBTM) is set to report Q2 earnings Monday. The prior quarter revenue was $936 million, up 9.6% year on year, and the company beat analysts on EBITDA and EPS. For the upcoming quarter, analysts expect revenue growth of 5.1% y/y. The article cites an average analyst price target of $178.75 versus a $138.47 share price.

Industrial stocks fell after Iran’s missile attack near the Strait of Hormuz pushed oil higher and revived inflation and rate concerns. The Industrial Select Sector SPDR (XLI) dropped ~2%; Brent neared $75 and WTI ~$71; the 10-year Treasury yield was ~4.47%. Shares of AYI, JBTM, and BLDR fell ~4% (BLDR -4.1%).

Wall Street Zen downgraded multiple stocks on June 21, including Predictive Oncology (AGPU) to sell from hold, Agape ATP (ATPC) to sell from hold, Bonk (BNKK) to sell from hold, Columbia Financial (CLBK) to sell from hold, and Camden Property Trust (CPT) to sell from hold. It also cut several ratings to hold or buy for companies such as Devon Energy (DVN), fuboTV (FUBO), and Alnylam (ALNY).

JBT Marel Corporation (JBTM) outlined plans at its 2026 Investor Day for focused acquisitions and improved margin through further savings, building on reported synergy realization of US$43 million. The company aims to add market-leading technologies and recurring revenue while applying clear cash return hurdles for deals. Investors are watching for sustained margin progress and successful integration, with identified risks including tariff exposure and merger execution.

JBT Marel Corporation announced that its segment realignment became effective for the fourth quarter of 2025, driven by the integration of its operating model after combining legacy JBT and Marel organizations. The company has recast its historical segment results in a Form 8-K. JBT Marel will report its fourth quarter and full year 2025 financial results on Monday, February 23, 2026, and will host an earnings conference call on Tuesday, February 24, 2026, at 10:00 AM ET.

JBT Marel has reorganized its reporting segments into Protein Solutions and Prepared Food and Beverage Solutions, effective Q4 2025. This realignment aims to reflect the integration following the Marel acquisition and update the CEO-reviewed reporting structure. Historical segment results for Q1-Q3 2025 and FY 2024/2023 have been recast, though this change does not affect past consolidated financial figures.